EPCT-17. A PHASE I AND SURGICAL STUDY OF RIBOCICLIB AND EVEROLIMUS IN CHILDREN WITH RECURRENT OR REFRACTORY MALIGNANT BRAIN TUMORS: PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT

Genomic aberrations in the cell cycle and PI3K pathway are commonly observed in recurrent childhood brain tumors. Dual inhibition of CDK4/6 (ribociclib) and mTOR (everolimus) has strong biologic rationale, non-overlapping single-agent toxicities, and adult clinical experience. The maximum tolerated...

Descripción completa

Detalles Bibliográficos
Autores principales: DeWire, Mariko, Fuller, Christine, Campagne, Olivia, Lin, Tong, Pan, Haitao, Young-Pussaint, Tina, Baxter, Patricia, Hwang, Eugene, Bukowinski, Andrew, Dorris, Kathleen, Hoffman, Lindsey, Waanders, Angela, Karajannis, Matthias, Steward, Clinton, Onar-Thomas, Arzu, Dunkel, Ira, Fouladi, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715686/
http://dx.doi.org/10.1093/neuonc/noaa222.139

Ejemplares similares

Ejemplares similares